Credit Suisse analyst Daniel Oppenheim downgrades Trex Co (NYSE:TREX) from Neutral to Underperform.
Noting Strong Progress On Marinus Pharma’s Lead Drug Ganaxolone, Analyst Initiates With 300% Upside
RBC Capital Markets initiated coverage on Marinus Pharmaceuticals Inc (NASDAQ:MRNS) with an Outperform rating, Speculative Risk, and a price target of…